- For pediatric familial hypercholesterolemia, statins are safe and effective according to the results of this meta-analysis of 10 randomized controlled trials.
Why this matters
- Statins are approved in the United States and Europe for pediatric use for ages 10 years and up.
- These authors say that nevertheless, their efficacy and safety for this population “are not well documented.”
- Vs placebo, statins were linked to average relative reductions (95% CIs) in:
- Total cholesterol: −25.5% (−30.4% to −20.5%; I2, 91%).
- Low-density lipoprotein cholesterol: −33.8% (−40.1% to −27.4%; I2, 90%).
- Triglycerides: −8.4% (−14.8% to −2.03%; I2, 26%).
- Apolipoprotein B: −28.8% (−33.9% to −23.6%; I2, 83%).
- They were linked to increases in high-density lipoprotein cholesterol:
- 3.1% (1.1%-5.2%; I2, 0%).
- Biomarkers (liver, muscle) did not differ with statin vs placebo.
- Adverse event incidence was similar between placebo, treatment (
- The analysis showed no effects on sexual development (Tanner stage) or growth.
- Meta-analysis of 10 randomized controlled trials with 1191 participants; ages, 13.3 ± 2.5 years.
- Funding: None disclosed.
- Statin types could not be compared head to head or dose to dose.
- Some missing data were imputed.